SALUTENSIN-DEMI
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SALUTENSIN-DEMI (SALUTENSIN-DEMI).
Salutensin-Demi is a combination of hydroflumethiazide, a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption, and reserpine, an adrenergic neuron-blocking agent that depletes catecholamines from peripheral nerve endings, reducing sympathetic outflow.
| Metabolism | Hydroflumethiazide is minimally metabolized; reserpine is extensively metabolized in the liver via CYP450 enzymes. |
| Excretion | Renal: hydrochlorothiazide 70% unchanged, reserpine <1% unchanged; fecal: reserpine ~6% as metabolites |
| Half-life | Hydrochlorothiazide: 6-15 hours (terminal), clinical effect lasts 6-12 hours; Reserpine: 50-100 hours (terminal), with prolonged action due to irreversible vesicular depletion |
| Protein binding | Hydrochlorothiazide: 40-68% (primarily to albumin); Reserpine: approximately 40% (to albumin and α1-acid glycoprotein) |
| Volume of Distribution | Hydrochlorothiazide: 0.2-0.4 L/kg (distributes in extracellular fluid); Reserpine: 5-10 L/kg (extensive tissue distribution, high affinity for adrenergic neurons) |
| Bioavailability | Oral: hydrochlorothiazide 65-75%; reserpine 30-50% (extensive first-pass metabolism) |
| Onset of Action | Oral: hydrochlorothiazide diuresis begins within 2 hours, peak in 4-6 hours; reserpine hypotensive effect in 3-6 days (gradual onset) |
| Duration of Action | Hydrochlorothiazide: diuretic effect ~6-12 hours; Reserpine: hypotensive effect persists for 1-6 weeks after discontinuation due to irreversible binding to amine storage vesicles |
1 tablet (15 mg hydrochlorothiazide + 0.075 mg clonidine) orally once daily, with titration based on blood pressure response.
| Dosage form | TABLET |
| Renal impairment | Contraindicated in GFR <30 mL/min. For GFR 30-50 mL/min: use maximum 1 tablet daily; monitor electrolytes and renal function. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% (e.g., every other day). Child-Pugh C: contraindicated due to risk of hepatic encephalopathy. |
| Pediatric use | Not recommended for pediatric use due to lack of safety and efficacy data; alternative agents preferred. |
| Geriatric use | Start with 0.5 tablet (7.5 mg hydrochlorothiazide + 0.0375 mg clonidine) once daily; monitor for orthostatic hypotension, electrolyte imbalance, and renal function; avoid in patients with high frailty. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SALUTENSIN-DEMI (SALUTENSIN-DEMI).
| Breastfeeding | Excreted in breast milk; M/P ratio not reported. Risk of infant hypotension and renal impairment. Use caution, monitor infant blood pressure and renal function. |
| Teratogenic Risk | First trimester: Possible risk of congenital malformations based on animal studies; human data limited. Second and third trimesters: Fetal hypotension, renal dysfunction, oligohydramnios, skull ossification delay. Avoid use unless benefit outweighs risk. |
| Fetal Monitoring |
■ FDA Black Box Warning
None.
| Serious Effects |
["Known hypersensitivity to sulfonamide-derived drugs (hydroflumethiazide)","Anuria","History of mental depression (reserpine-containing products)","Active peptic ulcer or ulcerative colitis","Concomitant use with MAO inhibitors"]
| Precautions | ["Electrolyte imbalances (hypokalemia, hyponatremia)","Orthostatic hypotension","Depression (reserpine component)","Potential for increased risk of non-melanoma skin cancer with thiazide diuretics","May exacerbate systemic lupus erythematosus"] |
Loading safety data…
| Monitor maternal blood pressure, renal function, electrolytes, fetal growth, amniotic fluid volume via ultrasound, and fetal heart rate. |
| Fertility Effects | No specific human data; animal studies show no significant effect on fertility. Potential for reversible alterations in spermatogenesis or ovulation with some antihypertensives. Monitor reproductive function in patients attempting conception. |